June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
The involvement of apolipoprotein E on intraocular angiogenesis
Author Affiliations & Notes
  • Yuhei Hashimoto
    Gifu Pharmaceutical University, Gifu, Japan
  • Shinsuke Nakamura
    Gifu Pharmaceutical University, Gifu, Japan
  • Haruka Takizawa
    Gifu Pharmaceutical University, Gifu, Japan
  • Kazuhiro Tsuruma
    Gifu Pharmaceutical University, Gifu, Japan
  • Masamitsu Shimazawa
    Gifu Pharmaceutical University, Gifu, Japan
  • Hideaki Hara
    Gifu Pharmaceutical University, Gifu, Japan
  • Footnotes
    Commercial Relationships Yuhei Hashimoto, None; Shinsuke Nakamura, None; Haruka Takizawa, None; Kazuhiro Tsuruma, None; Masamitsu Shimazawa, None; Hideaki Hara, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5603. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuhei Hashimoto, Shinsuke Nakamura, Haruka Takizawa, Kazuhiro Tsuruma, Masamitsu Shimazawa, Hideaki Hara; The involvement of apolipoprotein E on intraocular angiogenesis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5603.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Vascular endothelial growth factor (VEGF) is known as a pathological angiogenetic risk factor. The anti-VEGF antibodies are used for the treatment of diabetic retinopathy, but its efficacy is not long-lasting. Recently, it has been reported that Apolipoprotein E (Apo-E) participated in the pathological vascularization. Therefore, we focus on the role of Apo-E in the retinal neovascularization.

Methods: Proliferation of human retinal microvascular endothelial cells (HRMECs) was assessed in the presence of Apo-E2, -E3, or -E4 with or without VEGF. Apo-E3 was injected into the intravitreal body of the oxygen-induced retinopathy (OIR) model mice at postnatal day 14 (P14) and retinal neovascularization was quantified at P17. The localization and expression of Apo-E in the retina was also evaluated in the OIR model.

Results: In vitro, Apo-E2 and -E3 significantly further promoted VEGF-induced cell proliferation but Apo-E4 had no effect in HRMECs. In vivo, intravitreous injection of Apo-E3 increased the number of abnormal blood vessels and area on retina in the OIR model mice compared with normal mice. On the other hand, there was no significant difference in avascular area between each group. In addition, Apo-E was colocalized with retinal endothelial cell and the expression of Apo-E in OIR model mice increased more than that in the normal mice.

Conclusions: These data suggested that Apo-E2 and -E3 promoted the retinal neovascularization and they might become the new therapeutic drug targets.

Keywords: 700 retinal neovascularization • 499 diabetic retinopathy • 706 retinopathy of prematurity  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.